Sitemap | Contact Us  

Welcome To Taj Pharmaceuticals Ltd API

About Worldwide  |     FAQs    |    Careers     | |        Media Center  |  |    Taj Pharmaceuticals  World   | |     TAJ Group 

      © 2004 - 2009 Taj Pharmaceuticals Limited . All rights reserved

Desloratadine Taj Pharmaceuticals Ltd.

      India              Latin America/ Caribbean            Africa & Middle East              Asia              Russia              Europe  

Desloratadine Manufacturers in India Suppliers Desloratadine Exporters Distributors Desloratadine api active pharmaceuticals ingredients Desloratadine manufacturers Side Effects bulk drugs raw material Desloratadine companies Side Effects Importers Desloratadine Desloratadine Exporters Desloratadine exporters FDA Desloratadine DMF Symptoms Generic Taj Pharmaceuticals Ltd.

active pharmaceutical ingredients suppliers pharmaceutical Desloratadine manufacturing pharmaceutical drugs pharmaceutical intermediates Desloratadine pharmaceutical chemicals pharmaceutical raw materials Desloratadine active pharmaceutical ingredients Desloratadine committee active pharmaceutical ingredients manufacturer Desloratadine Active Pharmaceutical Ingredients manufacturer Desloratadine exporter drug ingredients pharmaceuticals

Pharmaceuticals API Manufacturer Desloratadine, Desloratadine manufacturer India, Desloratadine product, Desloratadine products, Api preparation, Certificate of Analysis API manufacturer product, Desloratadine anti ulcer product, Certificate of Origin COA Desloratadine COS Desloratadine, pharmaceutical generic, pharmaceutical drug, medical, Desloratadine pharma healthcare, pharma patents, contract MSDS manufacturing Trader Desloratadine pharma, generic pharma, HCL pharma MSDS pharmaceutical products, pharmaceutical formulations, generic import API, Desloratadine expectorant Pharmaceutical GMP Method of analysis formulations manufacturer, Desloratadine DMF drug master file pharmaceutical Anti Cancer active ingredient exporter from India, pharma Desloratadine ingredients, api, HIV Desloratadine, tablets, capsules, syrup & protein Desloratadine powder, GMP of Plant api nutraceuticals, gynec products, ortho ingredients in India, oncology products, Desloratadine gastroenterology products, buy, sell orthopaedic product, who gmp, cGMP, US FDA, Desloratadine WHO, UKMHRA Approval

   API >>>
   Pharmaceuticals API List
   Product Development
   Product Search
   Agro Chemicals
   Custom Pharma Services
   Contact Us








HOME >> API >> API List1 >> Desloratadine >> Pharmalogy

CAS Registry Number 100643-71-8

Desloratadine CAS Number 100643-71-8

Mechanism of Action

Desloratadine is a long-acting tricyclic histamine antagonist with selective H1-receptor histamine antagonist activity. Receptor binding data indicates that at a concentration of 2-3 ng/mL (7 nanomolar), desloratadine shows significant interaction with the human histamine H1- receptor. Desloratadine inhibited histamine release from human mast cells in vitro.

Results of a radiolabeled tissue distribution study in rats and a radioligand H1-receptor binding study in guinea pigs showed that desloratadine did not readily cross the blood brain barrier.
Desloratadine (a major metabolite of loratadine) is extensively metabolized to 3-hydroxydesloratadine, an active metabolite, which is subsequently glucuronidated. The enzyme(s) responsible for the formation of 3-hydroxy-desloratadine have not been identified. Data from clinical trials indicate that a subset of the general population has a decreased ability to form 3-hydroxydesloratadine, and are poor metabolizers of desloratadine. In pharmacokinetic studies (n= 3748), approximately 6% of subjects were poor metabolizers of desloratadine (defined as a subject with an AUC ratio of 3-hydroxydesloratadine to desloratadine less than 0.1, or a subject with a desloratadine half-life exceeding 50 hours). These pharmacokinetic studies included subjects between the ages of 2 and 70 years, including 977 subjects aged 2-5 years, 1575 subjects aged 6-11 years, and 1196 subjects aged 12-70 years. There was no difference in the prevalence of poor metabolizers across age groups. The frequency of poor metabolizers was higher in Blacks (17%, n=988) as compared to Caucasians (2%, n=1462) and Hispanics (2%, n=1063). The median exposure (AUC) to deslor-atadine in the poor metabolizers was approximately 6-fold greater than in the subjects who are not poor metabolizers. Subjects who are poor metabolizers of desloratadine cannot be prospectively identified and will be exposed to higher levels of desloratadine following dosing with the recommended dose of desloratadine. In multidoe clinical safet studies, where metabolizer status was identified, a total of 94 poor metabolizers and 123 normal metabolizers were enrolled and treated with CLARINEX for 15-35 days. In these studies, no overall differences in safety were observed between poor metabolizers and normal metabolizers. Although not seen in these studies, an increased risk of exposure-related adverse events in patients who are poor metabolizers cannot be ruled out.

Information Associated with Product:
Product Enquiry Product Quotation Sample Request Place Your Order  
Product Enquiry Product Quotation Sample Request Place Your Order  

Taj Pharmaceuticals API Logo


Api Manufacturing At Taj

Acamprosate Calcium

Clomipramine Hcl

Alendronate Sodium



Clopidogrel Bisulfate



Atomoxetine Hcl



Desmopressin Monoacetate


Divalproex Sodium


Dobutamine Hcl

Bupropion Hcl



Dothiepin Hcl






Escitalopram HBr





Cefuroxime Axetil



Fluticasone Propionate

Citalopram Hbr

Fluvoxamine Maleate

Fosphenytoin Sodium

Copyright © Taj Pharmaceuticals Ltd. | Privacy Policy | Terms & Conditions | Sitemap

Investor Relations    Feedback     Contact Worldwide    Sitemap


taj group logo
© 2004 - 2009 Taj Pharmaceuticals Limited . All rights reserved
Note:-We are committed to helping you find the right answers to your questions and concerns. However, this web site is not intended to give investment advice, promote the use of Taj Pharmaceuticals Ltd products or provide information on which to base medical treatment. If you have questions regarding any Taj Pharmaceuticals Ltd product or are experiencing a medical emergency, please consult your health care provider.
Additionally, contact information on this web site cannot be used to report adverse drug events. If you are a physician, please follow the procedures required by your country's regulations. Please choose one of the given options to contact us and we will respond to your inquiry as quickly as possible.